{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:13:09Z","timestamp":1790363589647,"version":"4.1.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The term spondyloarthritis (SpA) encompasses a heterogeneous group of inflammatory musculoskeletal diseases with several common genetic background and clinical features, including the possible involvement of the axial skeleton with peripheral mono- or oligo- arthritis and frequently coexisting skin, eye and intestinal manifestations. When the sacroiliac joints or other parts of the spine or thoracic wall are predominantly affected at magnetic resonance or X-ray imaging with inflammatory back pain, the disease is classified as axial SpA and the therapeutic choices are significantly different compared to cases of peripheral arthritis. Moving from the narrow effectiveness and safety profiles of non-steroidal anti-inflammatory drugs, there has been a significant research effort aimed at identifying new treatments based on our better understanding of the pathogenesis of SpA. Indeed, in parallel with the solid data demonstrating that IL-17 and IL-23 are key cytokines in the development of enthesitis and spondylitis, monoclonal antibodies interfering with this pathway have been developed for the treatment of axial SpA. Furthermore, the IL-17\/IL-23 axis is key to extra-articular manifestations such as inflammatory bowel disease, uveitis, and psoriasis which are frequent comorbidities of SpA. Currently available drugs act through these mechanisms recognizing IL-23 and targeting IL-17, such as secukinumab and ixekizumab. These therapeutic approaches are now envisioned in the international treatment recommendations for psoriatic arthritis with an axial phenotype as well as for ankylosing spondylitis (AS). We will provide herein a concise comprehensive overview of the clinical evidence supporting the use of these and other drugs acting on IL-23 and IL-17 in axial SpA.<\/jats:p>","DOI":"10.3389\/fimmu.2021.622770","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T10:45:51Z","timestamp":1622630751000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Clinical Trials Supporting the Role of the IL-17\/IL-23 Axis in Axial Spondyloarthritis"],"prefix":"10.3389","volume":"12","author":[{"given":"Angela","family":"Ceribelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Vecellio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasa","family":"Isailovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0294-7","article-title":"The IL-23-IL-17 Pathway as a Therapeutic Target in Axial Spondyloarthritis","volume":"15","author":"Sieper","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.6.2593","article-title":"T Cell interleukin-17 Induces Stromal Cells to Produce Proinflammatory and Hematopoietic Cytokines","volume":"183","author":"Fossiez","year":"1996","journal-title":"J Exp Med"},{"key":"B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.71.1.1","article-title":"Il-17: Prototype Member of an Emerging Cytokine Family","volume":"71","author":"Aggarwal","year":"2002","journal-title":"J Leukoc Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0801967","article-title":"Genome-Wide Comparison Between IL-17A- and IL-17F-induced Effects in Human Rheumatoid Arthritis Synoviocytes","volume":"182","author":"Zrioual","year":"2009","journal-title":"J Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 Rather Than interleukin-12 is the Critical Cytokine for Autoimmune Inflammation of the Brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/ni1497","article-title":"Development, Cytokine Profile and Function of Human Interleukin 17-Producing Helper T Cells","volume":"8","author":"Wilson","year":"2007","journal-title":"Nat Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60970-9","article-title":"Spondyloarthropathy: Interleukin 23 and Disease Modification","volume":"385","author":"Sherlock","year":"2015","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"Il-17 and Th17 Cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2007.10.007","article-title":"Th17 Cells: Effector T Cells With Inflammatory Properties","volume":"19","author":"Korn","year":"2007","journal-title":"Semin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.3HI1215-542R","article-title":"Human Mast Cells Capture, Store, and Release Bioactive, Exogenous IL-17A","volume":"100","author":"Noordenbos","year":"2016","journal-title":"J Leukoc Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00795","article-title":"A Reappraisal on the Potential Ability of Human Neutrophils to Express and Produce Il-17 Family Members In Vitro: Failure to Reproducibly Detect it","volume":"9","author":"Tamassia","year":"2018","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3895","article-title":"Il-12 and IL-23 Cytokines: From Discovery to Targeted Therapies for Immune-Mediated Inflammatory Diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab, an interleukin-17A Antagonist in the Treatment of Ankylosing Spondylitis or Radiographic Axial Spondyloarthritis in Patients Previously Untreated With Biological Disease-Modifying Anti-Rheumatic Drugs (COAST-V): 16 Week Results of a Phase 3 Randomised, Double-Blind, Active-Controlled and Placebo-Controlled Trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F Neutralisation by Bimekizumab in Psoriatic Arthritis: Evidence From Preclinical Experiments and a Randomised Placebo-Controlled Clinical Trial That IL-17F Contributes to Human Chronic Tissue Inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B16","first-page":"27","article-title":"Primary Efficacy of Netakimab, a Novel interleukin-17 Inhibitor, in the Treatment of Active Ankylosing Spondylitis in Adults","volume":"38","author":"Erdes","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24025","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a Human anti-interleukin-17A Monoclonal Antibody, in Patients With Psoriatic Arthritis (FUTURE 2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab Inhibition of Interleukin-17A in Patients With Psoriatic Arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13075-019-2055-z","article-title":"Secukinumab Efficacy on Resolution of Enthesitis in Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies","volume":"21","author":"Coates","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218808","article-title":"Secukinumab in Patients With Psoriatic Arthritis and Axial Manifestations: Results From the Double-Blind, Randomised, Phase 3 MAXIMISE Trial","volume":"80","author":"Baraliakos","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-eular.1576","article-title":"Ixekizumab for the Treatment of Patients With Active Psoriatic Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors: Results From the 24-Week Randomised, Double-Blind, Placebo-Controlled Period of the SPIRIT-P2 Phase 3 Trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13075-019-1831-0","article-title":"Ixekizumab and Complete Resolution of Enthesitis and Dactylitis: Integrated Analysis of Two Phase 3 Randomized Trials in Psoriatic Arthritis","volume":"21","author":"Gladman","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa189","article-title":"Safety of Ixekizumab in Adult Patients With Plaque Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Data From 21 Clinical Trials","volume":"59","author":"Genovese","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1744666X.2020.1803063","article-title":"Ixekizumab for the Treatment of Ankylosing Spondylitis","volume":"16","author":"Huang","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for Patients With non-Radiographic Axial Spondyloarthritis (COAST-X): A Randomised, Placebo-Controlled Trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1605352","article-title":"Il-17 Inhibition in Axial Spondyloarthritis: Current and Future Perspectives","volume":"19","author":"Torgutalp","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in Psoriatic Arthritis: Results From the Randomised Phase III AMVISION-1 and AMVISION-2 Trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10067-020-05207-z","article-title":"Molecular Mechanisms and Clinical Studies of Iguratimod for the Treatment of Ankylosing Spondylitis","volume":"40","author":"Liu","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2017.1390150","article-title":"Is Iguratimod Effective in Refractory Axial Spondyloarthritis","volume":"47","author":"Luo","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/art.40728","article-title":"Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","article-title":"Repeated Subcutaneous Injections of IL12\/23 p40 Neutralising Antibody, Ustekinumab, in Patients With Relapsing-Remitting Multiple Sclerosis: A Phase II, Double-Blind, Placebo-Controlled, Randomised, Dose-Ranging Study","volume":"7","author":"Segal","year":"2008","journal-title":"Lancet Neurol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001217","article-title":"Impact of Guselkumab, an interleukin-23 p19 Subunit Inhibitor, on Enthesitis and Dactylitis in Patients With Moderate to Severe Psoriatic Arthritis: Results From a Randomised, Placebo-Controlled, Phase II Study","volume":"6","author":"Mease","year":"2020","journal-title":"RMD Open"},{"key":"B34","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","article-title":"Dual Neutralisation of interleukin-17A and interleukin-17F With Bimekizumab in Patients With Active Ankylosing Spondylitis: Results From a 48-Week Phase IIb, Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Study","volume":"79","author":"van der Heijde","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in Biologic-Naive Patients With Active Psoriatic Arthritis (DISCOVER-2): A Double-Blind, Randomised, Placebo-Controlled Phase 3 Trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and Safety of Risankizumab in Moderate-to-Severe Plaque Psoriasis (UltIMMa-1 and UltIMMa-2): Results From Two Double-Blind, Randomised, Placebo-Controlled and Ustekinumab-Controlled Phase 3 Trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 Inhibitor, for Ankylosing Spondylitis: Results of a Randomised, Double-Blind, Placebo-Controlled, Proof-of-Concept, Dose-Finding Phase 2 Study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/art.40759","article-title":"Ustekinumab Fails to Show Efficacy in a Phase Iii Axial Spondyloarthritis Program: The Importance of Negative Results","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000719","article-title":"The IL-23\/IL-17A Axis in Spondyloarthritis: Therapeutics Informing Pathogenesis","volume":"32","author":"Siebert","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"102429","DOI":"10.1016\/j.autrev.2019.102429","article-title":"Critical Role of Interleukin (IL)-17 in Inflammatory and Immune Disorders: An Updated Review of the Evidence Focusing in Controversies","volume":"19","author":"Ruiz de Morales","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B41","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.immuni.2020.02.004","article-title":"Structural Analysis Reveals That the Cytokine Il-17f Forms a Homodimeric Complex With Receptor Il-17RC to Drive Il-17ra-Independent Signaling","volume":"52","author":"Goepfert","year":"2020","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190571","article-title":"Interleukin 17A and IL-17F Expression and Functional Responses in Rheumatoid Arthritis and Peripheral Spondyloarthritis","volume":"47","author":"Chen","year":"2020","journal-title":"J Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218456","article-title":"EULAR Recommendations for the Management of Psoriatic Arthritis With Pharmacological Therapies: 2019 Update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 Update of the ASAS-EULAR Management Recommendations for Axial Spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00382","article-title":"Anti-Tnf Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses","volume":"10","author":"Menegatti","year":"2019","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/art.40866","article-title":"A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23276","article-title":"Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study","volume":"69","author":"Dougados","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22848","article-title":"Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis","volume":"68","author":"Rudwaleit","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e001079","DOI":"10.1136\/rmdopen-2019-001079","article-title":"Treatment Retention of Infliximab and Etanercept Originators Versus Their Corresponding Biosimilars: Nordic Collaborative Observational Study of 2334 Biologics Naive Patients With Spondyloarthritis","volume":"5","author":"Lindstrom","year":"2019","journal-title":"RMD Open"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/art.40447","article-title":"Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis","volume":"70","author":"Yang","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126567","article-title":"TYK2 Inhibition Reduces Type 3 Immunity and Modifies Disease Progression in Murine Spondyloarthritis","volume":"130","author":"Gracey","year":"2020","journal-title":"J Clin Invest"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in Patients With Ankylosing Spondylitis: A Phase II, 16-Week, Randomised, Placebo-Controlled, Dose-Ranging Study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and Safety of Upadacitinib in Patients With Active Ankylosing Spondylitis (SELECT-AXIS 1): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2\/3 Trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and Safety of Filgotinib, a Selective Janus Kinase 1 Inhibitor, in Patients With Active Ankylosing Spondylitis (TORTUGA): Results From a Randomised, Placebo-Controlled, Phase 2 Trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2817","article-title":"Il-23 Induces Spondyloarthropathy by Acting on ROR-gammat+ Cd3+Cd4-CD8- Entheseal Resident T Cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.596086","article-title":"The IL-17\/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis","volume":"11","author":"Vecellio","year":"2020","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrrheum.2015.133","article-title":"Genetics of Ankylosing Spondylitis\u2013Insights Into Pathogenesis","volume":"12","author":"Brown","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0091-8","article-title":"Effects of the IL-23-IL-17 Pathway on Bone in Spondyloarthritis","volume":"14","author":"Gravallese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201915","article-title":"Efficacy and Safety of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Ankylosing Spondylitis","volume":"72","author":"Pathan","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez457","article-title":"Is Axial Psoriatic Arthritis Distinct From Ankylosing Spondylitis With and Without Concomitant Psoriasis","volume":"59","author":"Feld","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209853","article-title":"Axial Disease in Psoriatic Arthritis Study: Defining the Clinical and Radiographic Phenotype of Psoriatic Spondyloarthritis","volume":"76","author":"Jadon","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a Human anti-IL-17A Monoclonal Antibody, for Moderate to Severe Crohn\u2019s Disease: Unexpected Results of a Randomised, Double-Blind Placebo-Controlled Trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.298","article-title":"Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn\u2019s Disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence Rates of Inflammatory Bowel Disease in Patients With Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis Treated With Secukinumab: A Retrospective Analysis of Pooled Data From 21 Clinical Trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14528","article-title":"Association Between Psoriasis and Inflammatory Bowel Disease: A Danish Nationwide Cohort Study","volume":"175","author":"Egeberg","year":"2016","journal-title":"Br J Dermatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/art.22669","article-title":"Differences in the Incidence of Flares or New Onset of Inflammatory Bowel Diseases in Patients With Ankylosing Spondylitis Exposed to Therapy With Anti-Tumor Necrosis Factor Alpha Agents","volume":"57","author":"Braun","year":"2007","journal-title":"Arthritis Rheum"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.622770\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T12:10:45Z","timestamp":1672315845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.622770\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,2]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2021.622770"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.622770","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,2]]},"article-number":"622770"}}